JAP15 Rec'd PCT/PTO 28 AUG 2006

PTO/SB/21 (09-04)
Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork R	eduction Act of 1995. n	o persons	s are required to respond to a coll	ection of info	ormation u	nless it	displays a valid OMB control number.			
			Application Number 10/559,405							
TRANSMITTAL FORM		Filing Date	June 4, 2004							
		First Named Inventor	Patterson							
		Art Unit	Not Yet Kn							
(to be used for all correspondence after initial filing)		Examiner Name	Not Yet Kn							
Total Number of Pages in This Submission 4		<i>''y)</i>	Attorney Docket Number	53515AUS						
Total Number of Fages in	This Submission									
ENCLOSURES (Check all that apply) After Allowance Communication to TC										
Fee Attact Amendment/Reply After Final Affidavits/c Extension of Time Express Abandon Information Disclo Certified Copy of I Document(s) Reply to Missing F Incomplete Applic Reply to M	Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Remar		Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence A Terminal Disclaimer Request for Refund CD, Number of CD(s) Landscape Table on CD	Appeal Communication to Board of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please Identify below): PTO-1449 With Cited Refs. Return Postcard						
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT										
Firm Name		J. L. U	A THEORIES AT TO		IN AUE					
	Biosciences.									
Signature	DITTO 190	m	2.5/nm	\cap						
Printed name Jacque	Charles Country									
Date	/ >	1 5	1001a IF	Reg. No.	20.070					
Date HUD. 2), 2006 Reg. No. 30,279										
CERTIFICATE OF TRANSMISSION/MAILING										
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:										
Signature	ah	F/G	Rabl			116/65				
Typed or printed name Alishia L. Rowe-Babb		abb				Date	Ques 21.06			

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Patterson et al. : Group Art Unit: Not yet known

Application No.: 10/559,405 : Examiner: Not yet known

Filed: June 4, 2004 : Docket No. 53515AUSM1

For: AMIDINO COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

In accordance with 37 CFR §1.56 and 1.97 through 1.98, applicants which to make known to the Patent and Trademark Office the references cited from a foreign patent office on the attached form PTO-1449 (copies enclosed).

As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. §1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Commissioner is hereby authorized to charge the fee of \$180 and any other fees which may be required to facilitate this filing and credit any overpayments to deposit account 02-2117. Two copies of this paper are attached for this purpose. This is, however, not authorization to pay the issue fee.

Please acknowledge receipt of this IDS and kindly make the cited references of record in the above-identified application.

Respectfully Submitted, BERLEX BIOSCIENCES Customer No. 27586

Jacqueline S. Larson (Reg. No. 30,279)

uline 5 Lancon

Patent Attorney for Applicants

Berlex Biosciences 2600 Hilltop Drive P.O. Box 4099 Richmond, California 94804-0099 Telephone No. 510-669-4290 Facsimile No. 510-262-7095 Email: melissa shaw@berlex.com

FORM PTO-1449 U.S. DEPARTMENT OF COMME (REV.7-80) PATENT AND TRADEMARK OF				ATTY. DOCKET NO. 53515AUSM1				APPLICATION NO. 10/559,405				
	APPLICANTS Patterson et al.											
	FILING DATE June 4, 20	FILING DATE June 4, 2004			GROUP ART UNIT Not Yet Known							
U.S. PATENT DOCUMENTS												
*EXAMINER INITIAL	DOCUMENT NUMBER	DA	ATE NAME			CLASS	SUBCLASS		FILING DATE IF APPROPRIATE			
	None											
FOREIGN PATENT DOCUMENTS												
	DOCUMENT NUM	BER	DATE		COUNTRY				TRANS	LATION NO		
• -	WO/01/19816		March 22, 2001		PCT							
	WO/03/029200)	April 10, 2003		PCT							
	WO/00/51998	WO/00/51998		September 8, 2000		PCT						
	WO/02/069901	l	September 12, 2002		PCT							
	WO/01/19796		March 22, 2001		PCT							
	EP 0 623 627	EP 0 623 627		November 9, 1994		ЕР						
EXAMINER				DATE CONSIDERED								
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).												

Forms/Pat/P7-27 [01/31/01]